<DOC>
	<DOCNO>NCT02273700</DOCNO>
	<brief_summary>The main objective pilot study investigate protein / peptide plasma profile treatment direct anti-Xa ( activated Factor 10 ) patient non-valvular atrial fibrillation well understand mechanism action molecule perform exploratory analysis concern protein whose concentration change start treatment .</brief_summary>
	<brief_title>Plasma Modifications Associated With Rivaroxaban® Treatment Stroke Prevention</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>The patient correctly inform study , implementation , objective , associate restriction patient right The patient must give his/her inform sign consent The patient must insure beneficiary health insurance plan The patient available 1 month followup The patient nonvalvular atrial fibrillation diagnose within last 3 month . Documentation atrial fibrillation 12lead ECG , ECG rhythm strip , atrial fibrillation episode last least 30 second . The patient CHA2DS2VASc score = 1 , say presence least one follow risk factor : ( 1 ) congestive heart failure moderate severe systolic dysfunction leave ventricle ; ( 2 ) history systolic blood pressure &gt; 160 mmHg ; ( 3 ) diabetes ; ( 4 ) history ischemic stroke systemic embolism ; ( 5 ) vascular disease ( myocardial infarction , arterial disease ) ; ( 6 ) age &gt; 65 year ; ( 7 ) female . The patient start Rivaroxaban ( Xarelto® ) Nîmes University Hospital The patient participate another interventional study The patient participate another interventional study within past three month The patient exclusion period determine previous study The patient judicial protection , tutorship curatorship The patient refuse sign consent It impossible correctly inform patient The patient pregnant , parturient , breastfeed Presence mechanical heart valve valve disease Patient recieved another new direct oral anticoagulant Xarelto® previous three month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Xarelto®</keyword>
	<keyword>protein/peptide profile</keyword>
</DOC>